In This Article:
Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.
Healthcare Technology
The 9 healthcare technology stocks we track reported a slower Q4. As a group, revenues beat analysts’ consensus estimates by 2.3% while next quarter’s revenue guidance was in line.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 17.2% since the latest earnings results.
Tandem Diabetes (NASDAQ:TNDM)
With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.
Tandem Diabetes reported revenues of $282.6 million, up 43.6% year on year. This print exceeded analysts’ expectations by 0.6%. Despite the top-line beat, it was still a slower quarter for the company with a significant miss of analysts’ sales volume estimates.
“2024 was a pivotal year for Tandem, as we returned to strong sales growth both in and outside of the United States, while delivering industry-leading customer satisfaction,” said John Sheridan, president and chief executive officer.
Unsurprisingly, the stock is down 49.5% since reporting and currently trades at $16.97.
Read our full report on Tandem Diabetes here, it’s free.
Best Q4: Phreesia (NYSE:PHR)
Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care.
Phreesia reported revenues of $109.7 million, up 15.4% year on year, outperforming analysts’ expectations by 0.7%. The business had a strong quarter with a solid beat of analysts’ EPS estimates and full-year EBITDA guidance topping analysts’ expectations.
The market seems content with the results as the stock is up 1.3% since reporting. It currently trades at $24.19.
Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it’s free.
Weakest Q4: Evolent Health (NYSE:EVH)
Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.
Evolent Health reported revenues of $646.5 million, up 16.3% year on year, falling short of analysts’ expectations by 0.7%. It was a softer quarter as it posted a miss of analysts’ EPS estimates and EBITDA guidance for next quarter missing analysts’ expectations significantly.